3.84
-0.01(-0.26%)
Currency In USD
| Previous Close | 3.85 |
| Open | 3.89 |
| Day High | 3.89 |
| Day Low | 3.84 |
| 52-Week High | 12.7 |
| 52-Week Low | 3.36 |
| Volume | 1,070 |
| Average Volume | 10,758 |
| Market Cap | 141.6M |
| PE | -2.03 |
| EPS | -1.89 |
| Moving Average 50 Days | 4.05 |
| Moving Average 200 Days | 5.14 |
| Change | -0.01 |
If you invested $1000 in Molecular Partners AG (MOLN) since IPO date, it would be worth $195.42 as of May 19, 2025 at a share price of $3.84. Whereas If you bought $1000 worth of Molecular Partners AG (MOLN) shares 3 years ago, it would be worth $542.37 as of May 19, 2025 at a share price of $3.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Molecular Partners to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
26 minutes ago
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (
Molecular Partners Reports Financial Results and Highlights from Q1 2025
GlobeNewswire Inc.
May 15, 2025 8:00 PM GMT
Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinical data on first targeted Radio-DARPin therapy prog
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
GlobeNewswire Inc.
Apr 25, 2025 8:00 PM GMT
Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co